Fetal anemia
Fetal hemoglobin levels change with advancing gestation. Normal ranges have been established using percutaneous umbilical blood sampling, and fetal anemia is categorized as mild, moderate, or severe, depending on the degree of deviation from normal. 1 The most common cause of fetal anemia in the United States is red cell alloimmunization, and the primary cause of maternal alloimmunization is maternal sensitization to the D antigen of the rhesus (Rh) blood group system. 2 Since 1968, the administration of the rhesus immunoglobulin to all pregnant women in the United States at risk for alloimmunization has decreased the incidence of Rh-hemolytic disease from 45 per 10,000 total births (live births and stillbirths) to 10.2 per 10,000 total births. However, the availability of Rh immune globulin has not eliminated the problem of alloimmunizations, since more than 50 red blood cell irregular antigens have also been implicated in hemolytic disease of the newborn. Alloimmunization to irregular antigens is usually caused by incompatible red blood cell transfusions, since blood is routinely crossmatched only for the Rh and ABO groups. In the United States, the incidence of maternal alloimmunization to potentially clinically significant antigens has been estimated to be 35 per 10,000 live births. These "irregular" antigens will continue to be a problem because prophylactic immune globulin is not available to prevent these cases.
Invasive Diagnosis of Fetal Anemia by Amniocentesis and Cordocentesis
Amniocentesis and cordocentesis have been extensively used for the diagnosis and management of fetuses at risk for anemia caused by red cell alloimmunization. 3, 4 Cordocentesis is considered the "gold standard" test, and it accurately diagnoses the fetal hematologic status. However, this test carries a significant risk of complications, such as infection, bleeding, fetal bradycardia, premature rupture of the membranes, and fetal death. 5 Furthermore, in an at-risk pregnancy, one procedure may not be sufficient. If an initial sample does not demonstrate anemia, the risk for the development of anemia usually persists, and the timing and frequency of repeat cordocentesis is arbitrarily determined.
Traditionally, amniocentesis is used to select those cases that need cordocentesis.
However, this invasive test also has significant drawbacks. The best evidence for the reliability of amniotic fluid Delta OD 450 to predict fetal anemia is for pregnancies at greater than 27 weeks' gestation. The accuracy of amniocentesis for identifying anemic fetuses earlier in pregnancy is controversial. 6 Also, in spite of the extensive use of this procedure, there are no reliable data concerning the optimal frequency for repeated testing. Another drawback of using amniocentesis to select patients for cordocentesis is that 70% of the fetuses who are selected based on traditional amniotic fluid analysis are either non-anemic or mildly anemic ( Fig. 1 ). 1 Both cordocentesis and amniocentesis may cause worsening of the maternal alloimmunization, presumably secondary to fetalmaternal hemorrhage. Therefore, a fetus that is not initially severely anemic may become anemic and require a transfusion as a direct result of the invasive testing.
Noninvasive Diagnosis of Fetal Anemia
Several ultrasonographic and Doppler parameters have been used in the last 20 years to diagnose fetal anemia. The one that has received the most attention in recent years is the middle cerebral artery peak systolic velocity (MCA-PSV). In 1990 we published the first study demonstrating that the MCA-PSV was a better predictor of fetal anemia than the MCA pulsatility index. 7 In 1993, it was reported that the MCA-PSV had a sensitivity of 100% for detecting fetuses who had severe anemia caused by red blood cell alloimmunization. 8 However, in that study, the number of false positive results was high. In 1995, these results were confirmed in a prospective study, 9 and middle cerebral artery peak systolic velocity nomograms were developed (Table 1 ). In 1997, it was shown that the trend of the MCA was at least as good as that of the delta OD 450 for pre-FIGURE 1. Hemoglobin concentration in 111 fetuses that underwent cordocentesis because they had been defined as severely anemic based on traditional criteria. Lines representing the 5 th , 50 th , and 95 th percentiles for normal fetal hemoglobin are depicted. The line showing the border between mild anemia and moderate anemia is at 0.65 of the median for hemoglobin concentration, whereas the line separating those with moderate and severe anemia is set at 0.55 of the median. The filled dots represent the values of hemoglobin in fetuses with hydrops. 1 dicting fetal anemia. 10 Moreover, the assessment of the MCA-PSV was less expensive and less invasive than amniocentesis.
Despite the theoretical advantages of using the MCA-PSV instead of invasive methods, the technique did not gain widespread acceptance because of the limited number of patients in these initial studies. A multicenter study was therefore carried out to assess the feasibility of using the fetal MCA-PV as the primary means of determining which fetuses at risk for anemia will need intrauterine transfusion. This study found that the optimal MCA-PV cutoff for identifying moderate anemia was 1.50 multiples of the median (sensitivity of 100% with a 12% false positive rate) and 1.55 MoM for predicting severe anemia (sensitivity 100%, false positive rate 15%) 1 (Fig. 2) . This was the only study classified as level 1 evidence in a systematic review on noninvasive techniques to detect fetal anemia due to red cell alloimmunization. 11 Another multicenter trial with intentionto-treat analysis has monitored pregnancies complicated by red cell alloimmunization by studying the MCA-PSV longitudinally. 12 The results of this study are depicted in Figure 3 . In this group of fetuses, the decision to perform cordocentesis was based exclusively on the values of the MCA-PSV. This prospective study confirmed that the MCA-PSV is an accurate method of monitoring pregnancies complicated by red cell antibodies. However, this study showed that the number of false positive results increased after 35 weeks' gestation.
Most of the studies published in the last few years have confirmed that the MCA-PSV is an excellent tool to diagnose anemia, and may in fact be more suitable for the prediction of fetal anemia than the Delta OD 450. 13 Delle Chiaie et al 14 confirmed the presence of an inverse correlation between MCA-PSV measurements and hemoglobin values in fetuses at risk for anemia due to maternal blood group alloimmunization and fetal parvovirus B19 infection. Additionally, middle cerebral artery peak systolic velocity may accurately estimate fetal anemia in conditions such as fetomaternal hemorrhage, nonhimmune hydrops, and twintwin-transfusion syndrome. 15
Correct Technique for Sampling the Middle Cerebral Artery Peak Systolic Velocity
One of the advantages of using the middle cerebral artery peak systolic velocity is that it can be easily measured in most patients. Since most fetuses have the long axis of the head in a transverse plane, the angle of insonation between the ultrasound beam and the direction of blood flow can be kept very close to 0 degrees and, therefore, the peak systolic blood velocity may be accurately measured. When sonographers are approriately trained, this measurement has a low intra-and inter-observer variability. It usually takes from 5 to 15 minutes to accomplish. The steps necessary for the correct assessment of the MCA-PSV are as follows:
1. The fetus needs to be in a period of rest (no breathing or movements) for at least 2 minutes 2. The circle of Willis is imaged with color Doppler 3. The sonographer zooms the area of the MCA so that it occupies more than 50% of the screen. The MCA should be visualized for its entire length 4. The sample volume (1 mm) is placed close to the origin of the MCA from the internal carotid artery in such a way that the angle between the direction of blood flow and the ultrasound beam is as close as possible to 0 degrees. The angle corrector should not be used.
The waveforms (between 15 and 30)
should be similar to each other. The highest PSV is measured. 6. The above steps are repeated at least three times.
Why Does the Blood Velocity Increase During Anemia?
Animal studies have shown that the increased velocity seen in various vascular beds in anemic fetuses is due to increased cardiac output and a decline in blood viscosity. 16 In anemic human fetuses, there is a cubic relationship between the MCA-and the fetal hemoglobin prior to the first transfusion ( Fig. 4 ). It appears that initial small decreases in fetal hemoglobin only slightly change cardiac output and blood viscosity. When the anemia becomes more severe, the relationship between these parameters be- comes linear and the fetal hemoglobin value can accurately be estimated. 17 When this level has been reached, a minimal change in fetal hemoglobin will affect the blood velocity. At a certain point, as anemia becomes even more severe and fetal hydrops develops, cardiac output plateaus. This may explain why severely anemic fetuses with and without hydrops may have similar peak velocity readings. 
What is the Effect of Correction of Fetal Anemia on the Blood Velocity?
Middle cerebral artery peak systolic velocity has been shown to decrease acutely to the normal range after correction of anemia by intrauterine transfusion. 18 This normalization is seen after the first or subsequent blood transfusions. The fall in middle cerebral artery velocity after transfusion is thought to be due to an increase in cardiac afterload resulting from increased blood viscosity and improved oxygenation of fetal blood.
Can the MCA-PSV be Used for Timing the Second Transfusion?
MCA-PSV may be used to time the second fetal transfusion, but the MCA-PSV cutoff point to detect severe anemia following the first intrauterine transfusion is 1.69 MoM. 19 This is because the adult blood that was used in the first transfusion has decreased red cell size and cellular rigidity compared with fetal blood. These characteristics change the blood viscosity and, thus, the MCA PSV is slightly higher for a given hemoglobin concentration.
Prediction of Those Fetuses That Will Become Anemic
We performed serial MCA-PSV measurements on a group of 15 women with healthy fetuses, 8 with fetuses that became mildly anemic, and 11 with fetuses that were severely anemic at their first cordocentesis. 20 A linear model was fitted to the data from individual fetuses in these groups, plotting the change in MCA-PSA against gestational age. The average rate of change was compared among the three groups (Fig. 5 ). We found that slope of the curve, representing the rate of change in MCA-PSV, increased with the degree of anemia. Thus, not only the absolute MCA-PSV, but also a higher rate of change across time may help predict fetal anemia.
Monitoring At-risk Patients
We use the following protocol for monitoring pregnancies at risk for fetal anemia. Middle cerebral artery peak systolic values are obtained on a weekly basis once a fetus is identified to be at risk for anemia and once fetal cord sampling would be considered feasible. A value over 1.5 MoM is considered to be an indication for invasive testing with cordocentesis. If, after three values have been obtained, the MCA-PSV remains below 1.50 MoM, a regression line incorporating these values is calculated. If the plotted rate of rise in the MCA-PCV is to the right of the dotted line shown in Figure 5 , the examination is repeated every 2 to 4 weeks, based on the initial risk of the patient. For example, if a patient is sensitized to the D antigen with a titer between 1:16 and 1:32 and she never had an anemic fetus, the examination will be repeated in 4 weeks. With a higher initial risk, the examination will be repeated more frequently. If the plotted regression line is between the dotted and the thin lines shown in Figure 5 , the examination is repeated every 1 to 2 weeks, again 
928
Detti and Mari based on the initial risk of the patient. If the regression line is to the left of thin line, but the middle cerebral artery value remains below 1.50 MoM, the examination will be repeated in 1 week.
Conclusion
The middle cerebral artery peak systolic velocity is a powerful noninvasive tool to diagnose fetal anemia. We have used the MCA-PSV for clinical decision making in pregnancies at risk for red cell alloimmunization for the last 9 years. For the past 5 years, following a transition period during which this technique was used in conjunction with amniocentesis, the MCA-PSV has been used exclusively for clinical decision making. A recent survey of 300 perinatologists revealed that 70% were using the middle cerebral artery to diagnose anemia. We want to emphasize that although measurement of the MCA-PSV is relatively straightforward, it should not be used for making critical management decisions until the person doing the measurement receives adequate training in its use. This rule applies even to sonographers who are expert in other areas of prenatal diagnosis.
